| Name | Title | Contact Details |
|---|---|---|
Teresa Bair |
General Counsel and Senior Vice President of Administration | Profile |
Teresa Bair |
Executive Officer, General Counsel and Senior Vice President of Administration | Profile |
Particle Dynamics is a company that provides innovative technologies, quality ingredients, and custom processing capabilities that deliver solutions for the pharmaceutical, consumer health, OTC, and nutraceutical markets.
Inclinix Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Visus Therapeutics is a clinical-stage company in pursuit of developing the world`s first presbyopia-correcting eye drop with the potential to last at least eight hours. With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is VTI-001 (BRIMOCHOL™), a once-daily eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.
Zogenix is a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company has two late-stage development programs underway: FINTEPLA® (ZX008, fenfluramine oral solution) for the treatment of seizures associated with Dravet and Lennox-Gastaut syndromes, two rare and often-catastrophic childhood-onset epilepsies, and MT1621, a novel substrate enhancement therapy for the treatment of a rare genetic disorder called TK2 deficiency.